Cargando…

The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group

OBJECTIVE: The aim of this study was to prospectively investigate the efficacy and safety profiles of low-dose dasatinib therapy (50 mg once daily). METHODS: Patients with chronic myeloid leukemia in the chronic phase (CML-CP) who were being treated with low-dose imatinib (≤200 mg/day), but were res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iriyama, Noriyoshi, Ohashi, Kazuteru, Hashino, Satoshi, Kimura, Shinya, Nakaseko, Chiaki, Takano, Hina, Hino, Masayuki, Uchiyama, Michihiro, Morita, Satoshi, Sakamoto, Junichi, Sakamaki, Hisashi, Inokuchi, Koiti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799051/ https://www.ncbi.nlm.nih.gov/pubmed/29033428 http://dx.doi.org/10.2169/internalmedicine.9035-17

Ejemplares similares

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation
por: Kumagai, Takashi, et al.
Publicado: (2017)

Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment‐free remission
por: Kumagai, Takashi, et al.
Publicado: (2020)

New dosing schedules of dasatinib for CML and adverse event management
por: Wong, Siu-Fun
Publicado: (2009)

Chronic Myelogenous Leukemia (CML) in the elderly
por: Balducci, Lodovico, et al.
Publicado: (2014)

COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study
por: Rea, Delphine, et al.
Publicado: (2020)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
por: Masiello, David, et al.
Publicado: (2009)

Cytogenetic study in CML
por: Subramanian, P.G.
Publicado: (2012)

CML: Evolution and design
por: Murray-Rust, Peter, et al.
Publicado: (2011)

Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy
por: Shiseki, Masayuki, et al.
Publicado: (2017)

Cobicistat as a Potential Booster of Ponatinib and Dasatinib Exposure in a CML Patient: A Case Study
por: Hofman, Susan, et al.
Publicado: (2023)

The Role of Early Molecular Response in the Management of Chronic Phase CML
por: Harrington, Patrick, et al.
Publicado: (2017)

Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
por: Hehlmann, Rüdiger, et al.
Publicado: (2022)

New concepts for CML clonality
por: Khorashad, Jamshid S., et al.
Publicado: (2013)

Eradication of CML stem cells
por: Carter, Bing Z., et al.
Publicado: (2016)

Current treatment approaches in CML
por: Castagnetti, Fausto, et al.
Publicado: (2019)

The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients
por: Schubert, Claudia, et al.
Publicado: (2017)

Targeting a chronic problem: elimination of cancer stem cells in CML
por: Nerlov, Claus
Publicado: (2009)

Priapism in Patients with Chronic Myeloid Leukemia (CML): A Systematic Review
por: Ali, Elrazi, et al.
Publicado: (2021)

Appearance and Disappearance of Chronic Myeloid Leukemia (CML) in Patient with Chronic Lymphocytic Leukemia (CLL)
por: Payandeh, Mehrdad, et al.
Publicado: (2014)

Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
por: Glauche, Ingmar, et al.
Publicado: (2018)

Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
por: Bonifacio, Massimiliano, et al.
Publicado: (2021)

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
por: Hehlmann, R, et al.
Publicado: (2017)

Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms
por: Zizioli, Daniela, et al.
Publicado: (2021)

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
por: Cortes, Jorge E., et al.
Publicado: (2020)

CMLLite: a design philosophy for CML
por: Townsend, Joe A, et al.
Publicado: (2011)

The New ELN Recommendations for Treating CML
por: Hehlmann, Rüdiger
Publicado: (2020)

Diagnostic radiography as a risk factor for chronic myeloid and monocytic leukaemia (CML).
por: Preston-Martin, S., et al.
Publicado: (1989)

Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients
por: Şahin, Fahri, et al.
Publicado: (2013)

The UK SPIRIT 1 trial in newly-diagnosed chronic myeloid leukaemia (CML)
por: Gallipoli, Paolo, et al.
Publicado: (2022)

Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma
por: Ramdial, Jeremy L., et al.
Publicado: (2019)

Isodicentric Philadelphia chromosome: an uncommon chromosomal abnormality in the chronic phase of chronic myeloid leukemia (CML)
por: Loo, Eric, et al.
Publicado: (2015)

Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir
por: Azad, Niyaz A, et al.
Publicado: (2018)

Potential to Improve Therapy of Chronic Myeloid Leukemia (CML), Especially for Patients with Older Age: Incidence, Mortality, and Survival Rates of Patients with CML in Switzerland from 1995 to 2017
por: Daskalakis, Michael, et al.
Publicado: (2021)

Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review
por: Morozova, E.V., et al.
Publicado: (2015)

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
por: Hjorth-Hansen, Henrik, et al.
Publicado: (2015)

Human AQP5 Plays a Role in the Progression of Chronic Myelogenous Leukemia (CML)
por: Chae, Young Kwang, et al.
Publicado: (2008)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

Is Allogeneic Transplantation an Option in Patients Affected by Concurrent Myelofibrosis and Chronic Myeloid Leukemia (CML)?
por: Sora, Federica, et al.
Publicado: (2021)

On the Power of Additional and Complex Chromosomal Aberrations in CML
por: Greulich-Bode, Karin M, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bjg9jetrief2rt9ulfciknlns8